{
    "2019-06-25": [
        [
            {
                "time": "",
                "original_text": "【国盛医药张金洋团队】沃森生物：创新基因驱动发展，疫苗第二波大浪潮重磅产品处于审批尾声",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "创新基因",
                        "疫苗",
                        "第二波大浪潮",
                        "重磅产品",
                        "审批尾声"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：医药生物业周报 荐8股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "医药生物",
                        "周报",
                        "荐股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}